Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced results from its dose-escalating, double-blind, placebo-controlled Phase 2 clinical trial in 30 patients with dystrophic and junctional epidermolysis bullosa (EB), a severe “orphan” skin disorder with limited prevalence in the U.S. and Europe. RGN-137 (a topical formulation of Thymosin beta 4 or Tß4) was administered to a single non-healing index lesion in these patients daily for 56 days and followed for an additional 14 days post-treatment.
Help employers find you! Check out all the jobs and post your resume.
